Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Plus Fostamatinib in Steroid Refractory Chronic GvHD
NCT06233110Phase 1Recruiting
- Start
- Oct 2025
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fostamatinib in chronic graft-versus-host disease (cGVHD) (6 arms). Primary endpoint: Minimum safe and biologically effective dose at 6 months. Started Oct 2025; status: recruiting.
02
Drugs
fostamatinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06233110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233110.